ESMO 2019 | Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma

Name: Encouraging phase 3 CheckMate 238 data: adjuvant nivolumab in resected stage III/IV melanoma
Uploaded: 2019-09-29T00:00:00Z
Duration: 2 min 56 s
Description: Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, presents the results of the phase 3 CheckMate 238 trial (NCT02388906), which looked at adjuvant nivolumab vs. ipilimumab in resected stage III/IV melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.

Paolo Ascierto • 29 Sep 2019

ESMO 2019

Melanoma Skin Cancer Antibodies Ipilimumab Nivolumab

CheckMate 238

Paolo Ascierto, MD, National Tumor Institute, Milan, Italy, presents the results of the phase 3 CheckMate 238 trial (NCT02388906), which looked at adjuvant nivolumab vs. ipilimumab in resected stage III/IV melanoma. This interview took place at the European Society for Medical Oncology (ESMO) 2019 congress in Barcelona, Spain.